Drugs that contain Dexmedetomidine Hydrochloride
1. Dexmedetomidine Hydrochloride patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9717796 | HQ SPCLT PHARMA | Heat sterilizeable, premixed, ready to use dexmedetomidine solution packaged in a flexible plastic container |
Apr, 2036
(11 years from now) | |
| US9649296 | HQ SPCLT PHARMA | Heat sterilizeable, premixed, ready to use dexmedetomidine solution packaged in a flexible plastic container |
Apr, 2036
(11 years from now) | |
Market Authorisation Date: 21 October, 2015
Treatment: NA
Dosage: SOLUTION;INTRAVENOUS
DEXMEDETOMIDINE HYDROCHLORIDE family patents
2. Igalmi patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11786508 | BIOXCEL | Use of sublingual dexmedetomidine for the treatment of agitation |
Dec, 2037
(13 years from now) | |
| US11839604 | BIOXCEL | Use of sublingual dexmedetomidine for the treatment of agitation |
Dec, 2037
(13 years from now) | |
| US11517524 | BIOXCEL | Film formulations containing dexmedetomidine and methods of producing them |
Jun, 2039
(15 years from now) | |
| US10792246 | BIOXCEL | Film formulations containing dexmedetomidine and methods of producing them |
Jun, 2039
(15 years from now) | |
| US11478422 | BIOXCEL | Film formulations containing dexmedetomidine and methods of producing them |
Jun, 2039
(15 years from now) | |
| US11497711 | BIOXCEL | Film formulations containing dexmedetomidine and methods of producing them |
Jun, 2039
(15 years from now) | |
| US11806334 | BIOXCEL | Non-sedating dexmedetomidine treatment regimens |
Jan, 2043
(18 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Apr 05, 2025 |
Market Authorisation Date: 05 April, 2022
Treatment: Acute treatment of agitation associated with schizophrenia by sublingual or buccal administration; Acute treatment of agitation associated with bipolar i or ii disorder by sublingual or buccal adminis...
Dosage: FILM;BUCCAL, SUBLINGUAL
IGALMI family patents
3. Precedex patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US4910214 | HOSPIRA | Optical isomer of an imidazole derivative medetomidine as an alpha-2-receptor agonist |
Jul, 2013
(10 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US4910214 (Pediatric) | HOSPIRA | Optical isomer of an imidazole derivative medetomidine as an alpha-2-receptor agonist |
Jan, 2014
(10 years ago) | |
| US6716867 | HOSPIRA | Use of dexmedetomidine for ICU sedation |
Mar, 2019
(5 years ago) | |
|
US6716867 (Pediatric) | HOSPIRA | Use of dexmedetomidine for ICU sedation |
Oct, 2019
(4 years ago) | |
| US8242158 | HOSPIRA | Dexmedetomidine premix formulation |
Jan, 2032
(7 years from now) | |
| US10016396 | HOSPIRA | Dexmedetomidine premix formulation |
Jan, 2032
(7 years from now) | |
| US8338470 | HOSPIRA | Dexmedetomidine premix formulation |
Jan, 2032
(7 years from now) | |
| US8455527 | HOSPIRA | Methods of treatment using a dexmedetomidine premix formulation |
Jan, 2032
(7 years from now) | |
| US9616049 | HOSPIRA | Dexmedetomidine premix formulation |
Jan, 2032
(7 years from now) | |
| US8648106 | HOSPIRA | Dexmedetomidine premix formulation |
Jan, 2032
(7 years from now) | |
| US9320712 | HOSPIRA | Dexmedetomidine premix formulation |
Jan, 2032
(7 years from now) | |
|
US8455527 (Pediatric) | HOSPIRA | Methods of treatment using a dexmedetomidine premix formulation |
Jul, 2032
(8 years from now) | |
|
US8338470 (Pediatric) | HOSPIRA | Dexmedetomidine premix formulation |
Jul, 2032
(8 years from now) | |
|
US9320712 (Pediatric) | HOSPIRA | Dexmedetomidine premix formulation |
Jul, 2032
(8 years from now) | |
|
US9616049 (Pediatric) | HOSPIRA | Dexmedetomidine premix formulation |
Jul, 2032
(8 years from now) | |
|
US8242158 (Pediatric) | HOSPIRA | Dexmedetomidine premix formulation |
Jul, 2032
(8 years from now) | |
|
US8648106 (Pediatric) | HOSPIRA | Dexmedetomidine premix formulation |
Jul, 2032
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Dec 16, 2025 |
| New Indication(I-577) | Oct 17, 2011 |
| M(M-61) | Jun 17, 2016 |
| Pediatric Exclusivity(PED) | Dec 17, 2016 |
Market Authorisation Date: 31 January, 2020
Treatment: Intensive care unit sedation, including sedation of non-intubated patients prior to and/or during surgical and other procedures; Use for sedation
Dosage: INJECTABLE;INJECTION
PRECEDEX family patents